Data For Prothena's NEOD001 To Be Presented At The 58th Annual American Society Of Hematology Meeting

DUBLIN, Ireland, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, today announced that clinical data from its NEOD001 Phase 1/2 dose-escalation and expansion study will be highlighted in two oral presentations, and data highlighting quality of life measures in patients with AL amyloidosis will be featured in three posters at the 58 th Annual American Society of Hematology (ASH) Meeting to be held December 3-6, 2016, in San Diego, CA.

Clinical results of the Phase 1/2 dose-escalation and expansion study as of a May 9, 2016 data analysis were presented at the International Symposium on Amyloidosis (ISA) in Uppsala, Sweden on July 5, 2016. The two upcoming oral presentations at ASH will highlight additional aspects of the study results, as outlined below.

(Abstract #644) NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction: Results from the Expansion Cohort of a Phase 1/2 Study
  • Presenter:  Morie A. Gertz, MD, Professor of Medicine, Mayo Clinic
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 7:15 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain updated patient case study data.

(Abstract #647) Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response
  • Presenter:  Michaela Liedtke, MD, Stanford Comprehensive Cancer Center
  • Session:  653. Myeloma: Therapy, Excluding Transplantation: Amyloidosis
  • Date and Time:  Monday, December 5, 8:00 AM PT
  • Location:  San Diego Convention Center, Hall AB

This presentation will contain data demonstrating that patients treated with monthly NEOD001 infusions had favorable organ response rates that were independent of time since prior plasma cell dyscrasia (PCD) treatment, depth of hematologic response, or predominant type of PCD treatment.

If you liked this article you might like

3 Stocks You Probably Never Heard Of Could Catch Fire Soon

Prothena Raises $155.3M to Bring Anti-Organ Failure Drug to Market

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Prothena (PRTA) Is Today's Perilous Reversal Stock